drugset / Trial / NCT01131559
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
Phase 3
Terminated
50 enrolled
Lindner Center of HOPE
Shire · collabUniversity of Cincinnati · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lisdexamfetamine | Other / unclassified | 20 mg | Oral |
| Comparator | Lisdexamfetamine | Other / unclassified | 70 mg | Oral |